CIZZLE BIOTECHN. LS-0001
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more
CIZZLE BIOTECHN. LS-0001 (E7F0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CIZZLE BIOTECHN. LS-0001 (E7F0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CIZZLE BIOTECHN. LS-0001 - Net Assets Trend (None–None)
This chart illustrates how CIZZLE BIOTECHN. LS-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CIZZLE BIOTECHN. LS-0001 (None–None)
The table below shows the annual net assets of CIZZLE BIOTECHN. LS-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CIZZLE BIOTECHN. LS-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CIZZLE BIOTECHN. LS-0001 Competitors by Market Cap
The table below lists competitors of CIZZLE BIOTECHN. LS-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ChowChow Cloud International Holdings Limited
NYSE MKT:CHOW
|
$4.63 Million |
|
VivoSim Labs, Inc.
NASDAQ:VIVS
|
$4.63 Million |
|
Stavely Minerals Ltd
AU:SVY
|
$4.64 Million |
|
Akora Resources Ltd
AU:AKO
|
$4.64 Million |
|
Global Oriental Bhd
KLSE:1147
|
$4.63 Million |
|
Legacy Gold Mines Ltd.
V:LEGY
|
$4.63 Million |
|
CREF Equity Index Account - R2
NASDAQ:QCEQPX
|
$4.63 Million |
|
Mitra International Resources
JK:MIRA
|
$4.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CIZZLE BIOTECHN. LS-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CIZZLE BIOTECHN. LS-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CIZZLE BIOTECHN. LS-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CIZZLE BIOTECHN. LS-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CIZZLE BIOTECHN. LS-0001 (E7F0) | €- | N/A | N/A | $4.63 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |